title: [Use of sorafenib in patients with hepatocellular or renal carcinoma].
abstract: Therapeutic approaches of cancers have been recently improved by the development of targeted therapies. Amongst these new drugs, some anti-angiogenic molecules have been approved by either the EMEA or the Food and Drug Administration. Sorafenib, one of these inhibitors of angiogenesis, has been established as the standard of care for advanced hepatocellular and renal carcinoma. This paper reviews the safety profile of sorafenib and presents guidelines for the prevention and the treatment of the main side effects associated with this molecule.
authors.affiliation: Service d'hépatologie, hôpital Saint-Antoine, 184, rue du Faubourg St-Antoine, 75012 Paris, France. olivier.rosmorduc@sat.aphp.fr <olivier.rosmorduc@sat.aphp.fr>
authors.forename: O
authors.initials: O
authors.lastname: Rosmorduc
authors.forename: C
authors.initials: C
authors.lastname: Chevreau
authors.forename: P
authors.initials: P
authors.lastname: Dielenseger
authors.forename: S
authors.initials: S
authors.lastname: Ederhy
authors.forename: F
authors.initials: F
authors.lastname: Goldwasser
authors.forename: J-D
authors.initials: JD
authors.lastname: Grange
authors.forename: L
authors.initials: L
authors.lastname: Mortier
authors.forename: M-E
authors.initials: ME
authors.lastname: Neidhardt-Berard
authors.forename: C
authors.initials: C
authors.lastname: Robert
authors.forename: F
authors.initials: F
authors.lastname: Scotté
authors.forename: J-F
authors.initials: JF
authors.lastname: Seitz
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced / Q000517:prevention & control; D005221:Fatigue / Q000139:chemically induced / Q000517:prevention & control; D005533:Foot Dermatoses / Q000139:chemically induced / Q000517:prevention & control; D006229:Hand Dermatoses / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000517:prevention & control; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib